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                                 INTRODUCTION 
Need  for  the  study: 
 
                         Metabolic  syndrome  has  affected  more  than   25%   of   
the  population  in   the  western  civilisations.  MetS   is  a  major  
determining  factor  for  the  early  onset  of    insulin  resistant   diabetes  
&   accelerated atherosclerosis.  MetS  is  clinically  a  conglomeration   
of  risk  factors  highlighted   by   the  presence  of  systemic  
hypertension,  altered  lipid  profile,  dysglycemia,  proinflammatory  &  
prothrombotic  states. 
                               Sub-clinical  hypoT  &   MetS  are  well  established  
risk  factors  for   atheromatous-occlusive  vascular  diseases,  
dyslipidemia,  low  grade  persistent  inflammatory  state  and      pro-
coagulable  state.  This  association  may  be  in  part  be  explained  by  
thyroid  hormone’s   regulatory   effect  on   lipid  metabolism  and  
blood pressure. 
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                               MetS   and  sub-clinical/overt  thyroid  dysfunction   
are  independent  risk  factors, in  the  genesis  of   cardiovascular  
diseases.  Hence,  it  is  plausible   that  persons    affected   with   both  
these  conditions,  could   have  more  than  additive  hazard.  
                          This  study  is  a  step  towards  ascertaining  the  
possible  positive  link  of  thyroid  dysfunction  with  the  components  
of   MetS. 
                              In  this  study,  TSH  has  been  used  as  the  prime  
indicator  of  thyroid  dysfunction,  as  it  increases  before  the  elevation  
of  FT4  and  also  before  clinical  manifestation.      
 
Review   of   literature:  
 
                                            In  a  study  conducted  by  Texas  
University,  involving   greater  than  1,600  adults,  investigators  
noticed  that  persons  with   MetS   have   statistically   significant   
serum  TSH  levels  in  comparison  to   healthy  control  population.  In  
addition,   subclinical   hypoT  was   found  to  be  positively  associated  
with  increased  TGL  levels  &  elevated  blood  pressure. On  the  other  
      
 
10 
hand,  modest  increase  in  TSH  could  place  people  at  excess  risk  
for  development  of   MetS. 
                      Several  studies  have  shown  a  significant  association 
which  links  metabolic  syndrome  with  subclinical  and  overt 
hypothyroidism  and  the  association  seems  to  be  more  in  females.  
Uzunlulu  et  al   reported  that  the  prevalence  of  subclinical 
hypothyroidism  was  greater  in  women  with  MetS. 
                     In  a  study  by  Bauer  DC  et  al,  it  was  concluded  that  
among  older  hispanic  women,  elevated  TSH  levels  were  associated  
with  hazardous  changes  in  composition  of  lipids  &  that  women   
with   multitude  lipid  abnormalities  were  thrice  as  likely  to  have  
increased  TSH levels. 
                   The   study   conducted  by  Tromso  and  Basel,   has  
proven   that  thyroxine  supplementation,  in  patients  with  borderline  
thyroid  dysfunction,   has  a   better  effect  on  low  density(LDL)  
cholesterol  values.  This   also  led  to   relative  risk  reduction  in  
cardiovascular  morbidity  of  9–31%.  This  benefit  being attributed  to   
observed  reduction  in  serum  low  density(LDL)   cholestrol  levels. 
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                  A  study  conducted  by  HUNT, proposed   that  “Within  the  
range  of TSH  that  is  considered  clinically  normal,  increasing  level  
of  TSH was  associated  with  less  favorable  lipid  concentrations.  The 
association  with  serum lipids  was  linear  across  the  entire  reference 
range  of  TSH”. 
                 Research  published  in  the  February  2007  issue  of  the 
“Journal  of   Clinical  Endocrinology  and  Metabolism”  found   a 
connection  between  thyroid  function &  metabolic  syndrome.  In  
euthyroid  persons  ie   TSH  within  normal  levels,  the  level  of   free  
T4  was  important.  Free  T4  levels  that  were  slightly  low, but  still  
within  the  normal  range,  significantly  increased  the  risk  of many  
risk  factors  for  metabolic  syndrome. 
                In  hypothyroidism ,  energy  metabolism  is  reduced  leading 
to  a  decreased  in  appetite ,  cold  intolerance,  reduced  protein 
synthesis ,  lipid  accumulation(elevated  TG  and  LDL-Cholesterol). 
                 Study  by  L.Chandra  et  al  revealed  a  varied  effect  of 
thyroid  status  on  the  components  of  metabolic  syndrome.  The 
observed  changes  are  statistically  significant  within  and  between 
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euthyroid ,  hypothyroid , hyperthyroid   having  metabolic  syndrome 
and  the  group  not  having  metabolic  syndrome. 
                                 In  a  study  conducted  by Banaras  University,   
atherogenic  lipid  abnormalities  were  observed  in  adult  subjects  
with  Subclinical  hypothyroidism-2 (TSH > 10.0 Miu/L),  and  not  in 
subjects  with  Subclinicalhypothyroidism-1  who  had  TSH ≤ 10.0 
Miu/L in  Indian  population. 
                    The  Jaipur  Heart  Watch  Study   has  shown    that  in 
urban   adult   populations,  the    prevalence  of  MetS   was  nearly  
19%  in  men,  30%  in  women,  and   approximately  25%   on  the  
whole.                        
                          As  per  the  CURES 52  study,  elevated  BP  is  evident 
in   around  one-fifth  of   the  population  in  chennai.  Amidst  those 
hypertensive  patients,  the  presence  of   other  defining  characters  of  
MetS  was:  type2-diabetes  in  31.8%,  IGT   in  17.9%,  dys-lipidemia  
in  38.8%,  hypertriglyceridemia  in  38%,  high  visceral  adiposity  in  
64.3%   and  high  BMI  in  40%.  
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                                   In  a  population  based  study  conducted  by, 
“Prevention  of  Metabolic  Disorders  Research  Center,  Iran”,   
of  over  900  reproductive  aged  women,   subclinical  thyroid 
dysfunction  was  found  to  be  significantly  related  with  two 
components   of  MetS- low HDL  and  high  TGL. In  addition,  the 
average  estimated  total  score  of   MetS  in  women  with  SCH  was 
significantly  higher  than  the  euthyroid  women. This  has  been  also 
observed   that  TSH  levels  were  negatively  correlated  with  HDL-C 
and  positively  with  diastolic  blood  pressure  independently  of   well-
known  MetS  risk  factors.  
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                           Metabolic  syndrome  is  characterised  by  accumulation 
of   multiplex  of  risk  factors  that  roots  from  insulin  resistance, 
henceforth   accompanied  by  abnormal  adipose   tissue  deposition 
and  function. 
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                          This  is  one  of  the  most  important  problems   faced  
by  the  modern  fraternity  in  the  last  two  and  half  decades.  
Problem   statement: 
 About  25%  of  the  world’s  adult  population   has  metabolic 
syndrome. 
 People  with  metabolic  syndrome  three  times  as  likely  to 
have  a  heart  attack  or  stroke  compared  with  people 
without  the  syndrome. 
 People  with  metabolic  syndrome  have  a  five-fold  greater 
risk  of  developing  type 2  diabetes. 
 People  with  metabolic  syndrome   two   times  as  likely  to 
have  a  cardio  vascular  mortality,  as  compared  with 
people  without  the  syndrome. 
 This  puts  metabolic  syndrome  way  ahead  as  a  giant  
killer  disease,  yet  the  problem  is  not  as  well  recognised. 
                   Hence   earlier  diagnosis  is  needed  to  stop  this  
global  time  bomb. 
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HISTORY: 
                             Long  before  the  modern  definition  of   MetS,  the 
Italian  physician,  Morgagni,  described  the  association  between 
visceral  obesity,  arterial   hypertension,  atherosclerosis  and   high 
levels  of  uric  acid  in  blood,  almost  250  years  ago. 
                                 In  1920, Nicolae  Pautescu,  suggested  diabetes  and 
obesity  as  the  consequent  phases  of  same  pathological  phases.  In 
1988,  Reaven G.,  an  endocrinologist,  interpreted  the  association  of 
diabetes  mellitus,  hypertension  and  dyslipidemia,  by   their 
pathogenic  relationship  with  peripheral  insulin  resistance.  He  
named  this   “Syndrome X”.  
                        Ferranini  et  al,  confirmed  this  association  and  named 
it  ‘Insulin  resistance  syndrome’.  Soon  metabolic  disturbances,  was 
found  to  be  involving  larger  spectrum. Zimmet & co,  put  forward  
“Syndrome X  Plus”,  associated  with  sedentary  life  style, 
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hyperuricemia,  obstructive  sleep   apnea  etc.  In  1998,  WHO 
formulated  the  first  official  definition  of  MetS. 
IDF  definition:  
                       For  a  person  to  be  diagnosed  to  have  MetS,  he/she 
should have,         c                   
                    Central  obesity,  defined   as  waist  circumference  with   
ethnic   specificity,  >90cm   for  asian  men  and  >80cm   for   asian  
women. 
   Plus  any  two  of   the  following  criteria 
 
Raised   triglycerides 
                   > 150 mg/Dl  (1.7 mmol/L) 
                   (Or) on   specifi c  treatment  for  this  lipid  abnormality 
Reduced  HDL   cholesterol 
                 < 40 mg/Dl (1.03 mmol/L) in  males 
                 < 50 mg/Dl (1.29 mmol/L) in  females 
                      (Or) on  specifi c  treatment   for  this  lipid  abnormality 
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Raised   blood  pressure 
                   Systolic  BP  130mm of Hg & above 
                  (or) Diastolic  BP  85 mm Hg & above 
                  (or) 0n  treatment   of  previously  diagnosed  hypertension 
Raised  fasting  blood  sugar 
Table 1: The FPG > 100 mg/Dl (5.6 mmol/L), 
                   (or) previously  diagnosed  type 2  diabetes 
If  above  5.6 mmol/L  or 100 mg/Dl,  OGTT   is  strongly 
recommended   but   is   not   necessary   to   define   presence   of   the 
syndrome.nthe following four factors: 
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Prevalence: 
                                 The  exact  prevalence  varies  according  to  extent  
of  westernisation,  lifestyle  patterns  and  economic &  cultural 
patterns  prevailing  in  the  area. Indian  studies  have  shown  that  the 
prevalence  is  more  than  30%  in  urban  population  and  is  still 
swelling.  Gender  difference  is  significant,  with  the women  leading 
the   charts. Prevalence  is  1.5- 2  times  higher  in  women  compared 
to   men.  
                               There  has  been, also,  a  recent  surge  in  prevalence 
among  the  rural  Indian  population.  Alarming  increasing  childhood 
obesity  rates,  is  a  cause  for  concern. These  factors  indicate  the 
menace,  we  are  about   to  face  in  the  near  future.  
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Risk   factors   for  MetS: 
       Ethnicity 
                          Asian  Indian  phenotype,  is  predisposed  to  the 
development  of   MetS.  This  is  characterised  by  higher  body  fat 
with  comparatively,  lower  BMI.  The  proportion  of   intra-abdominal 
visceral  fat  is  much  higher  compared  to  lean  body  mass,  in  asian 
adults.  Hence  asian  phenotype,  has  higher  prevalence,  earlier  
onset  and  increased  complications  of  T2DM  at  lower  BMIs. 
 
                   Obesity 
                             Higher  the  body  weight,  higher  the  prevalence  and 
risk  of  development  of  MetS.  Increased  waist  circumference  is  a 
positive  predictor  of  future  development  of   MetS. 
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  DIET 
                                   There  has  been  a  decline  in  the  intake  of 
traditional  foods,  in  the  recent  two  to  three  decades.  Traditional 
Indian  foods  had  higher  fibre  content  and  was  lower  in  simple 
sugars  and  saturated   fat.  The  food  composition  has  varied  a  lot 
now-a-days.  Higher  consumption  of  animal  fats,  dairy  products  and 
hydrogenated  oils,  has  been shown  to  have  a  higher  correlation 
with  the  development  of  cardiovascular  diseases.  These  changes  in 
dietary  patterns  may  be  implicated  in  the  increased  incidence  of 
metabolic  syndrome. 
                Physical activity 
                                  Increased  mechanisation  of  work,  increased 
indoor  entertainment  activities  and  reduced  outdoor  activity,  has 
resulted  in  decreased  physical  activity  on  the  whole.  Finally 
resulting  in  increased  weight and  waist  circumference. 
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  Migration 
                                  An   adverse  coronary  risk  profile  has  been 
reported  among  rural-to-urban  migrant  population.  This  has  been 
suggested  due  to  significant  stress  arising  out  of  new  environment, 
job  challenges,  socio-economic  disparities,  lack  of  social  support 
etc.  
                    Genetic and environmental factors    
                                 Adverse  intrauterine  environment,  has  been 
linked  to  insulin  resistance  and  metabolic  syndrome. Low  birth 
weight  is  associated  with  high  SBP,  insulin  resistance,  fasting 
hyperinsulinemia.  Catch  up  obesity  seen  in  LBW  offspring  seems  to 
be  important  for  adult  onset  insulin  resistance  and  associated 
cardiovascular  risk  factors. 
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Psychological factors 
                                Stress  activates  sympathetic  nervous  system  
leading  to  hormonal  fluctuations.  Stress  has  been  associated  with 
hypertension,  which  is  an  integral  part   of   metabolic  syndrome. 
Pathophysiology 
                                Resistance  to the  action  of  insulin  is  the  corner 
stone  for  the  altered  metabolic  state  of  the  MetS.  Altered   free 
fatty  acid metabolism  is  the  prime  component  involved  in  the  
pathophysiology  of  dysglycemia  and  hyperlipidemia.  Increased  
plasma  FFA   concentration  impairs  the  ability  of  insulin  to  
stimulate  muscle glucose   uptake  and  suppress  hepatic  glucose  
production.  In addition,   high  levels  of  free  fatty  acids  delivered  to  
the  liver  increases  hepatic  very-low  density  lipoprotein  triglyceride 
production  and   plasma  triglyceride  concentration. An  increase  in 
plasma  triglycerides  increases  the  transfer  of  triglyceride  from  
VLDL  to  high  density  lipoprotein,  resulting  in   increased  high  
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density  lipoprotein  clearance  &  decreased  serum   high  density 
lipoprotein(HDL)  levels. 
                          Adipose  tissue  secretes  many  pro-inflammatory 
mediators (adipokines).  These  result  in   resistance to  insulin  action.  
For example,  TNF-alpha  reduces  insulin  signaling,   IL-6  increases  
inflammatory  reaction  directly   &   stimulates  hepatic-CRP    
production,  MCP-1  is  a   strong  chemotactant  for  macrophages , and  
IL-8  is  activator  for  neutrophil  granulocytes  &    chemoattractant  for  
most  of  the   described  migrating  immune  cells.  This  chronic  
inflammatory   process  leads  to  heightened  insulin  resistance.      
                              Excessive   intrahepatic  steatosis  is  associated  with   
impaired  hepatic  insulin  action.  This  also cause  reduced  insulin-
dependent  suppression of  nocturnal   glucose  release  from  liver.  
Excessive  muscle  fat   is  related  to   insulin  resistance.  This  also   
impairs  insulin-dependent  glucose  disposage. 
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                         Pictorial   representation  of  pathogenesis   of  MetS 
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MetS  and  CVD  risk: 
                                Overall,  the  metabolic  syndrome   is  associated  
with  a   two-fold  increase  in  risk  of  CVD,  CVD mortality,  and  
stroke.  There  has  been  also   a  1.5-fold  increase  in  risk  of   all-
cause mortality.  Patients  with  the  metabolic  syndrome,  but  without  
type 2 diabetes  mellitus,  are  still  at  high  risk  for  CVD  mortality,  
MI,  and stroke.  The  metabolic  syndrome  does   not   require   type 2 
diabetes mellitus  in  order   to  be  closely  associated  with  
cardiovascular  risk. 
                          Many   meta-analyses  have  shown  that  the   metabolic 
syndrome  is  associated  with  higher  cardiovascular  risk  in  women 
relative  to  men.  Several  theories  have  been  postulated  to  explain  a 
potentially  higher  cardiovascular  risk  in  women  with  the  metabolic 
syndrome .  
                 1) central  adiposity  tends  to  be  more  pronounced  in  
postmenopausal  women  than  in  men.  
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                 2) The  cholesterol  profile  is  different  in  women compared 
with  men.  HDL  cholesterol  decreases  and  LDL  cholesterol 
Increases  post-menopausally.  Also   LDL  particles  becoming 
denser,  and  therefore,  more  atherogenic.  
               3) Elevated  triglycerides  are  more  highly  associated 
with  coronary  artery  disease  in  women  than  in  men.  In 
a   meta-analysis,  it  was  shown  that  an  increase  in  triglycerides 
of  18 mg/dl  was  associated  with  a   76%   increased 
cardiovascular  risk  in   women  compared  with   a  32%   increased 
risk  in  men .  
                4) Presence  of   other  unique  risk  factors  like   polycystic 
ovary  syndrome,  hormonal  contraceptive  use,  and  gestational 
diabetes   may  be  responsible  for  a   stronger  association   between 
the  metabolic  syndrome  and  cardiovascular  risk  in  women.                        
The   key  mechanism  behind  elevated  CVD  risk  is attributable   to  
the  proinflammatory  and   prothrombotic   state associated  with  MetS.    
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Pro-inflammatory   state:  
                               Insulin   resistance  and  obesity  have  been  closely  
linked  to  a  pro-inflammatory  condition. The  main reason  being   
excessive  cytokine synthesis & release  of  acute phase reactants.        
C-Reactive protein is  one  of  the  important  acute  phase  reactant,  
mainly   produced  in  liver, after  any   noxious  stimuli.   Data         
from  prior  scientific  researches    have  shown  an  association  
between  serum  CRP  levels   and  features  of   MetS .  CRP  levels      
closely   predicts  the  development  of    T2DM   and  Cardio-vascular  
diseases.  
                                The liver being prime reign of systemic 
inflammatiory process,  chronic exposure to pro-inflammatory  
mediators  occurs.  This  results  in  excess  production of   many  of  the   
acute phase reactants, like  CRP.  Persistent  low  level inflammation  
noticed   in  obese  population,  causes  persistent  elevation  of pro-
inflammatory mediators. The major mediators  are  TNF-α,  IL-6,  and  
IL-8.  All   these  inflammatory  mediators  induce    resistance  to  
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insulin   action,  the   prime   target   being   hepatic  tissue  and  
muscles. 
 
      Pro-coagulant   state  
                                  Pro-coagulant  state  is  being  an  important   
ally     of  MetS. Many   factors  have  been suggested  to  be  associated 
in  hemostasis  regulation  in  MetS. The main haematologic  
abnormality  associated  with  MetS   is the  excessive  levels of  
Plasminigen  activator inhibitor-1.  It is the important suppressor of 
fibrinolysis. Community level  studies have concluded     that  excessive 
levels of  PAI-1 is a  fore-teller  of  myocardial  ischaemia &  CV 
mortality.  Hepatic fat  accumulation  is the  major reason for  increased  
plasma PAI-1 levels  in  persons  having  MetS.  
                                 MetS is related to excessive amount  of  plasma 
fibrinogen, factor-7  & factor 8. This  leads to the  procoagulable 
condition. Fibrinogen,  being  acute-phase    reactant,    is  produced by  
the hepatic tissue. Elevated  levels of  serum  fibrinogen  is  related  to   
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both  the   chronic persistent  inflammatory process &  resistance  to 
insulin  in  MetS.  
                               Even-then, the  exact   mechanism  behind   the excess  
production  of  fibrinogen  from  the  hepatic tissue  is  yet  to  be  
cleared.  This   has been  proposed  that  Free fatty acids   and  
inflammatory  mediators  linked  to  insulin resistance,  promote   the 
hepatic  production of clotting  factors.               
Pro-atherosclerotic   state:  
                               Fattyacid  binding  proteins  by  integrating   
metabolic  &  immune  responses,  interlink  the  inflammatory  and  
lipid-mediated  pathways.  This  mechanism  plays  a  vital  role   in  
MetS.  Thus   FABPs  are  causative  in  the  process  of  atherosclerosis 
,  mainly  by  modifying  cholesterol  trafficking   & inflammatory  
processes.  The  FABPs  thus,  implicate  a  longlasting  impact  on  
visceral  adiposity,  insulin  resistance,  diabetes  mellitus  &  Non-
alcoholic  fatty  liver  disease. 
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                         Thus,  MetS  is  a  pro-inflammatory,  pro-coagulant  and 
pro-atherosclerotic state, resulting  in  elevated  cardiovascular  risk.  
 
Management  of   MetS: 
 
                            The  efficient  treatment,  involves  optimal  control  of  
the     risk  factors  promoting    development  of  MetS.  By  
implementing lifestyle  interventions  remains  the  cornerstone  of  
management. Intensive  life-style  changes  involving   diet  and  
physical  activity,   is  the  recommended   first-line  treatment.  
Pharmacological therapy   is advised,  when the  lifestyle  changes  do  
not  produce  optimal  response.  Pharmacological  therapy,  is  needed  
in   persons  with  a  cardiovascular   risk  score  more  than  20% .  
 Life  style  modifications:  
 
                                 Most  of   the  persons   with   MetS  are either  
obese  or  overweight.  They  have  to  undergo  a   weight  losing  
program.  . A  optimal  achievable  target   is  a  6% to 10%    weight  
reduction  over  a  period  of  six  to  nine  months.  
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                               Adult  Treatment  Panel III  suggests  a  well  
balanced  diet,  with   reduced  consumption   of  refined  and  simple   
sugars.  Trans  fatty  acids   have  to  be  avoided.  Fresh  fruits,   
vegetables,  and  whole  grains  have  to  be  consumed  in  large  
proportions.  Nutritionists   have  suggested,  a  daily  reduction  of  
about   500–1000 kCal  is  the  easiest  way  for  a continued  weight  
reduction,  along  with  a  well-scheduled,  well-adhered  phsical  
activity     programme. 
                        The  most  recent AHA   recommendations,  suggest   a  
moderate intensity  exercise  regimen, for  atleast  a  period  of  not  less 
than  thirty  mts.  Brisk walking  and  bicycling   are  the  most  favored  
exercise  programme.  All  the  sedentary  activities  in  our   daily  
routine  life   has  to   be  avoided.  Whenever   possible,  healthy 
lifestyle  habits  have  to  be  adopted,  for  example,  going  to  shopping  
by  walk,  utilizing  steps instead  of  using  lifts/travellators.  All  these  
have  to  be  made  a  daily  routine. 
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Specific  Management  of  Metabolic  Risk  Factors:                                                         
.                       The  exact  objective   of  treating  MetS  is  to  decrease   
the  heightened  risk  of  cardiovascular  diseases   &   to  slow down the 
development  of   diabetes  mellitus.  A   multitude  of  residual  ongoing  
pathologic  changes  happening  in  MetS  have to  be  answered.  This  
may  not  be  achieved  even after,  optimizing, life-style  changes.  In  
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these  circumstances, pharmacological  therapy,  with  a  combination  of  
drugs,  is  necessary. 
 
 
Pharmocologic  interventions: 
                  Metformin, TZDs – for  dysglycemia  management. 
  Fibrates &statins – for  dyslipidemia  and  pleiotropic  effects.  
                   ACEI/ARBs  - for BP control and micro angiopathy protection. 
                   Aspirin       - for  negating the  procoagulant  state. 
                        
 
 
Insulin resistance and glucose intolerance:  
                       Insulin  resistance  associated  with    impaired  glucose  
tolerance  and  elevated  blood  sugar  levels  is  the   hallmark  feature  
of   MetS.  Hence  treatment  of  insulin  insensitivity  can  modify  both  
glucose  intolerance  and  dyslipidemia.  A  dietary  pattern  with  a  
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reduction  in  simple  sugars  &  saturated  fats,  in  hands   with  easily  
adoptable    exercise  program  is  the  main modality of  therapy .  
                           Drugs  that  enhance  insulin  sensitivity,  like  the  
biguanides (metformin)  and   the  thiazolidenediones,  
(PPARγagonists),  have  the  efficiency  to  either  slowdown/ prevent 
the  development  of  diabetes mellitus.  These  drugs   also  help  in  
modifying   the  metabolic  profile.  Thus  they  decrease   risk  of   
atherosclerosis.                    
                         In  a    Diabetes  Prevention  Study  conducted  in  
Finland,   a  total  of  522  persons  with  MetS,  rigourous   lifestyle  
modifications  decreased  the  risk  of   diabetes    to  58% ,  in  
comparison  to  the   controls.  In  the   DPP  study,  metformin in  the  
dosage  of  850 mg  bid   decreased  the  development  of  diabetes  
mellitus  by 31%.  In  the  same  study,  vigorous  lifestyle  changes  
reduced  the  risk  to  58%  in  comparison  to  placebo.  Inspite  of  
earlier  encouraging  results,  these  drugs  did  not  show   any  
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reduction  in  risk  of  CVD.  Hence  such  drugs  should  not   be  
prescribed  for  the  sole  purpose  of  prevention. 
Dyslipidemia:  
                   Lifestyle  intervention  with  dietary  changes  and  physical  
activity  is   the  prime  therapy  of  dyslipidemia  in  the  MetS.        
Eventhough   raised   Low Density   cholesterol  is  a  non-defining  
aspect  of   the    lipid  constitution   in  these  patients, 
LDL-C  and    apo-B  lipoproteins   are  pro-atherosclerotic.  LDL  
reduction  therapy  has  to  be  as  per  the  cardiovascular  risk  score.  
                         -in  persons  with  ≥ 20%   risk  as  calculated  by 
the  presence  of  CAD  or  CAD risk  equivalents,    the  desired   LDL  
level   is  less  than 100 mg/Dl. 
                          -patients  with  medium   risk  ie 10 – 20%   have  to    
achieve  a  desired   LDL  level   <130mg/dl. 
                           In  persons   with  elevated   TGL  levels,  more  than  
200 mg/dl,  increased  quantity  of   pro-atherosclerotic  remnant 
particles  like  Very Low & Intermediate Density cholesterol,  are  being  
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overlooked,    by  targeting  mainly  the  Low Density  cholesterol.  
Hence ,  Adult Treatment Panel III   generated   the  idea  of  non-HDL  
cholesterol.   This   includes  all  the  dangerous  atheroma-prone   
lipoprotein  subdivisions.  Non-High Density Cholesterol  target is  
30mgs%  more  than the  LDL  levels.   This  has  to  be  used  when  
TGL   level is   more  than   200 mgs%. 
                       In  such  persons  who  fail  to    reach  the  desired  
targets,  with  intensive  lifestyle  interventions,  pharmacological  
treatment   with  statins  has  to  be  started.  Lipid  lowering  drugs  
decreased    unwanted  cardiovascular  events  and  CVAs  in  many   
clinical trials. The  lipid  lowering  therapy,  had  additional  beneficial  
effects  in  diabetes  patients.  This  has  been  documented  in   
Collaborative  Atorvastatin  Diabetes  Study  &   
Heart  Protection  Study.   This  has  been  proven,  even  when  the      
cholesterol  is  within  normal  limits.  Statins   decrease  all  the     
apoB– lipoproteins . they    successfully  reach   Adult Treatment    
Panel III  targets  for  the   Low Density &  non-High Density  
cholesterol  in  persons  having  MetS. 
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                         Fibric  acid  congeners  modify  majority  of   the  
components   of  the  atherogenic  lipid  consitution  in    MetS. This  
improves  mainly  the  decreased HDL  ,  elevated  TGLs   and  small,   
dense  LDL  particles.  Their  use  has  to  be  thought  of  in   all  
persons  with   a  risk  of  more  than  20%  for  CAD.  Nicotinic  acid  at  
higher  dosage,  also  modifies   HDL  &  TGL  levels,  with  the  
comparable   efficiency   to  fibrates.  On the  downside,  nicotinic  acid  
causes  impaired  glucose  tolerance  &  elevates  serum  uric  acid  
levels.  Hence,  this  can not  be  used    in  persons  with   MetS. 
 
 
 
Procoagulant   &  proinflammatory  condition:    
                        In  MetS,   inflammatory  mediators  such  as ,  
Interleukin-6  and  Tumor Necrosis Factor–α  and  acute  phase  proteins  
like,  C-Reactive protein  and  fibrinogen  are  elevated.      PAI-1  levels  
are  mainly  increased.  Tissue plasminogen  activator  activity  is   
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decreased.  This    contributes   to  the characteristic  inflammatory-
prone   &   procoagulant  environment    of  the  MetS.   
                                 The  therapeutic  and  prognostic  role   measuring   
inflammatory  mediators  is  doubtful.  This   is  an  upcoming   area   of   
scope   in  preventive  cardiology.   Eventhough  assessment  of  
fibrinogen  &  procoagulation  factors  is  not  routinely  advised. 
AHA  current  recommendation is  for    anti-platelet  prophylaxis  in  
persons   with  a   more  than  10%  risk  for  CAD. 
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       SUB-CLINICAL   HYPOTHYROIDISM  
 
Definition:  
                                         SCH  is  defined  as  a  serum  thyroid-
stimulating  hormone  (TSH)  level  above  the  upper  limit  of 
normal  despite  normal  levels  of  serum  free  thyroxine.  TSH 
levels  5.5–10.0 Mu/l   correspond  to  prevalence  of  SCH. 
                                The  incidence  of  subclinical hypothyroidism   ranges  
from   6  to   8% ,  based  upon  the  sex , age  and  ethnicity of  the  
subjects  studied.  The  effects   of  subclinical hypothyroidism      
depends  upon   the  duration  and  the  degree  of  thyroid  dysfunction 
as   measured  by   TSH.    
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Effects  of  Thyroid  Hormones  on  Lipid  Metabolism: 
                           Thyroid  hormones  play  an  influential  role  in   most  
of   the  steps  of   lipid  metabolism  including  production,  transport  
and  storage.  Thyroxine   promotes  the  cholesterol  production  by  
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potentiating  the  action  of   HMG co-A  reductase, present   in  the  
hepatic  parenchyma.  
                      Thyroxine  induces  the  action  of    LPL.  Thus  results  in    
increased  hydrolysis  of    TGLs  into   VLDL. Also  the    chylomicrons  
are   hydrolysed  as  free  fatty acids  &  glycerol. In  thyroxine  
deficiency,   the  LPL  action  level   over   the  fatty  tissue  is  
documented  to  be  either  normal  or  suppressed.   In  the  mean  time,    
hepatic  lipase  action  is  also  suppressed,  causing  elevated  measures 
of   TGLs.  
                        Thyroxine  levels   also  directly   affect  the   CETP  
levels  and  action.    Reduced  thyroxine,  decreases  CETP  activity.  As  
a  result    both  total & subfraction   of   HDL    levels   are  markedly  
decreased.   Biologically  active   form,  T3,  stimulates  reseptor  gene  
expressivity.  This  results  in  augmented   clearance   of  Low  Density  
Cholesterol.  Also  the  T3,  increases  7-alpha  hydroxylase  activity.  
All  these  cumulatively  explain  the  decreased   Low  density   
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cholestrol  clearance  and  hence,  increased  serum  low  density  
cholesterol  levels  in  SCH.  
Lipid  metabolic  disturbances  in  SCH: 
                     Hyperlipidemia  is  a  very  common  laboratory  
abnormality  in  persons    with   evidence  of   hypothyroidism,  
including    elevated  levels  of   both  total  &  Low density  cholesterol.  
Researches  pertaining   to   TGLs,  Lp(a),  HDL,  apoB   &  apoA1 
components   in  subclinical  hypothyroidism    are  minimal.   In  
addition to  the  quantitative  changes,  qualitatives  changes  like,  
smaller,  denser  and  more  oxidized  Low density  cholestrol  is  a  
routine  feature  of  hypothyroidism. 
                           Both    qualitative  and  quantitative  changes   in  total  
&   Low density   cholesterol  are  directly  linked  to  measure  of    
thyroid   levels  in   SCH.  After  thyroxine  replacement  therapy, there  
occurs  a  significant  improvement  in  these  abnormalities.  But  TGLs,  
apoB,  apoA1, Lipoprotein-a levels,  may  or  may  not  be  adequately  
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controlled  after  therapy.  This   suggests  a  highly  perplexed   etiology  
for    lipid  abnormalities  in  SCH. 
                           Not  only  overt  hypoT,  but  also  the   SCH   is  also  
linked  to  profound  lipid  composition.  The  changes    include   the  
elevated  total  &  low density  cholesterol.  Whereas   HDL, TGLs,    
apoB,  Lp-a   &  apoA1  levels  did  not  show  marked  changes    
subclinical  hypothyroidism   when  compared  to  the  euthyroid  
controls , in    most   of  the  observations.  Rondeau et al.  noticed  a  
negative  correlation   between  HDL-C  and  TSH  levels    in   obese  
and   postmenopausal  females.  
                            Most    of   the  researches  have  found  that  after  
thyroxine  replacement  treatment,  both  the   total  &  Low density  
cholesterol  levels  are  being  normalized .  Whereas  hormone  
replacement studies  in  SCH,  have  shown  that  the  therapy  has  only  
a  limited  influence  over  the  serum  levels  of   TGLs,  apoA1,  HDL,  
apoB  &  Lp-a.  Reduced  transfer  of  TGLs  to  high density  cholestrol   
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&   phospholipids  in  SCH   was  corrected   after   achieing      
euthyroid   status.  
Hemodynamic   effects   of   thyroid  dysfunction: 
                            In   overt   hypoT,  the  prime  modifications  of    
cardiovascular  functions,   noticed  are  reduction  in   heart  rate, 
increased  peripheral  vascular  impedance,  elevated   diastolic  blood 
pressure  &  hence,  the  afterload.  Also  there  occurs   reduced  blood  
volume  &  hence,  the  preload.   Put  together,   cardiac  output  is  
diminished.  During  exercise,   left  ventricular  systolic  contractility  is  
impaired.   Also,  the  LV  diastolic  relaxation   is   reduced   during   
both  rest  &   exercise.  These  changes  occur  both  in   the  overt  &  
subclinical  hypoT.  In  elderly,  hypoT   is  associated  with  diastolic  
dysfunction  of  the  heart.   
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Thyroid  Dysfunction   &  Atherosclerosis: 
                        
                         Thyroid  dysfunction  is  associated  with  the  highly  
atherogenic  dyslipidemia. In  addition,   insulin  insensitivity,  
hypertension,  inflammation, oxidation  stress  &  coagulation  
abnormalities  are  enhanced  by  thyroid  dysfunction.  These factors  
prove  that  a  multitude  of  risk  factors  for  atheroma  formation,  in  
thyroid   dysfunction,  dyslipidemia  playing  a  major  part.  
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                           Clinical   hypoT   is  related  to  elevated  diastolic  
blood  pressure  and  hyperhomocysteinemia.  Increased  levels of  hs-
CRP  and  coagulation  deficits  have  also  been  reported  in patients  
with  hypothyroidism.  The  proposed  mechanisms  being, impairment   
of    intracellular  glucose  metabolism  &  translocation GLUT4.    
Enhancement  of  carotid  artery   intimal  thickness,   is  also  being   
noticed   in  persons  with  both  clinical/subclinical    hypoT. 
                               In  a  survey  conducted  in   Whickham ,  a  positive    
correlation   has  been  documented   between  the  incidence   of    CAD  
and  associated  mortality  in  persons  with   SCH,   followed  over  a  
period  of  two  decades.  This  positive   correlation  was  abolished  
after  thyroxine   replacement  therapy .  
                             Extending   support  to   this  observation,  many  
meta-analyses  suggest  that  SCH  is  related  to  a  marked rise  in   risk  
of   CAD   &  associated  mortality.  In  a  meta-analysis done   by  
Razvi et al., in  patients  younger  than  65 years   old ,   the  incident  
rate   of  CAD  and  associated  mortality,  found  to  be  elevated   in  
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persons   with  SCH.  This  is  more true   in  case  of   women.  SCH  is  
also  causally,  linked  with  the  incidence  of   cerebral  ischemia. 
Rodondi  et  al.  noticed  a   correlation   between  SCH  &  the  risk  of  
ischaemic  stroke.  
 
 
 
SCH  and  CV  Disease Risk: 
                            The   CV   modifications   observed   in   SCH 
patients   qualitatively   resemble   those  produced   by  overt 
hypothyroidism,  quantitatively,  to  a  lesser  extent.   Early alterations  
of  cardiac  performance,  endothelial  function, systemic  blood  
pressure,  and  lipid  profile  have  been documented  in  SCH  patients.  
This  supports   a  biologically plausible  role  for  subclinical  
hypothyroidism   in  the development  of  early  atherosclerosis.     
                              Serum  lipid  abnormality  is  prevalent  in  sub-
clinical  hypothyroidism,   and  it  is  considered  to  cause  
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cardiovascular  disorders.   Furthermore,  it  has  been  reported  that 
SCH  is  associated  with  high  serum  total  cholesterol  and   LDL 
levels  and  low  HDL  which  could  increase  the   atherosclerosis   risk.  
                                          A   significant  correlation   between  SCH  &   
CAD  morbidity  and  death    has  been  documented ,  although less  
evident  in  older  people.  The  relationship  between  SCH and  CHD  
persisted  even  after  adjustment  for  traditional  risk factors.  This   
suggests  an  alternative  mechanism  by   which SCH  increases  CV  
risk,  at  least  in  younger  individuals.  
                             Although  the  scientific  literature  is  not uniform  in  
the  definition  of  the  effect  of  SCH  with  mild  TSH elevation (<10 
Mu/L)  in  terms  of  CV  events  and  mortality, available  data  suggest  
an  impact  of  this  clinical  condition only  in  younger  patients (<65 
y),  especially  men. 
                               In   another  study   on  SCH  and  its  cardiac 
impacts,  diastolic  cardiac  dysfunction  in  the  resting  period  and 
systolic  dysfunction  in  the  exercise  period  and  a  reduced  exercise 
capacity  were  reported. 
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Treatment  guideline  for  SCH: 
                      In    most  of  the    patients  with   subclinical  hypo-T,  
there  is  no  need  for   treatment.  Oral  Levo thyroxine  is  the 
drug  of  preference, in  case  of   a  decision    to  treat  the  deficiency.   
Clinical  trials  of   subclinical  hypo-T   patients,  have  proven   that  
thyroxine    therapy  is  effecient  in  reducing  TSH   to   the  normal  
reference range.    
                           Ideally,  thyroxine   has  to  be   started  at  a  dose  of    
25-50 µg  od.  Followed  up  with  a   monthly    dosage   adjustment  to 
achieve   the  desired  TSH   value.  In  a  study,  100  elderly  persons   
>65yrs   of  age,  achieved  the  desired   TSH   level,  with  a   
replacement  dose  of  50µg  of   thyroxine .  In  two  more   RCTs,    
done  in   young   subclinical  hypo-T  persons , it  has  been  proven  
that   on  an  average,  thyroxine    at  a  dose  of  50-75 µg   is   needed  
to   bring   TSH  level  into  the  normal.                                        
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                            In  an  another  study,  involving   35  subclinical  
hypo-T   persons , it  has  been  that,  on  an  average  100 µg  of   
thyroxine,  is  needed   to  maintain   TSH  levels  between  0.5  -  2.5 
Mu.  In  a  large  clinical  study,   all  subclinical  hypoT  patients,  when    
started  on  100 µg  thyroxine   od,  discovered  
that  only  10%  developed   features  of   hyperthyroid   as  evidenced   
by  low   serum  TSH  and   increased  T 4  levels . Henceforth,  the 
thyroxine   dosage  of    50 – 100 µg   od   is  sufficient     to   bring  
down   TSH,  to  desired  levels  in  most  of  the   persons. 
                          In  many  situations,  the  patient  has  to  be  started  on    
the  approximate  full  dose  of  thyroxine . The  exception  being,  
known  patients  with  coronary  arteriak  heart  disease.  In  such  
patients,  much   lower  doses  have  to   be  started, followed  by    
gradual  stepwise  dose  escalation.  For  example,   in  a  patient with  
stable  angina,  thyroxine   has  to   be  started  &   increased  slowly   by  
25 µg  once  in    2- 3  weeks. Eventhough  a  quiet  identitical  approach  
is    undertaken  in  elder  persons,  especially  >70  yrs  of  age,  a  RCT   
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has   shown  that  such  a  cautious approach  is  not  needed  in  elder   
population , without  any   cardiac  disease. 
                            For    maximal  bioavailability,  thyroxine   has  to   be  
consumed  on  an  empty  stomach.  Studies  have  given  varied   results  
with  regard  to  the  ideal  time  for  thyroxine  replacement  therapy.  A   
study   conducted  in  United  States   population,  showed  adequate   
TSH  control,  if   thyroxine   is  consumed  on  an  empty  stomach  
state,  one  hour  before  food .  But  in  a  Denmark  study,   thyroxine   
consumed  just  before   bedtime  is  higher  in  efficacy,  when  
compared  to  that  consumed   one  hour   before  breakfast.   
                            There    are  many  drug-food  interactions.  Milk,  
coffee,  soya   &  papaya   especially  hamper  thyroxine   absorption.   
In   reality,  a  lot  of   medications  including 
Salts  of  calcium & iron,  antacids   such  as  sucralfate,  
H 2  blockers  &  PPIs,  result  in  significant   interference  to    
absorption  of   thyroxine .                
                           Likewise,  a  lot  of   GI  conditions  tend  to  negatively  
impact   on  absorption  of  thyroxine.  Some  of  such  conditions  are    
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atrophic gastritis, celiac  sprue &  pernicious  anaemia.  Both  
impairment   & improvement  of  thyroxine  absorption  are  documented 
following   various  types  of   bariatric  surgery .  Patients   falling  in  
these  situations  tend  to  need  increased  dosage  of   thyroxine.  
                             There  is  a  possible  theoretical   advantage  by   
combining  T 3 &T4  medication.  But   so  far, studies   using 
Combination  of   T 3&T4  medications  did  not  document   any  
definite  advantage   in  patients  with  clinical    hypoT.          
                             Also,  in   a   meta-analysis  of  studies  involving    
more  than  1,500  hypoT   persons,  no  convincing  advantage  of         
T 3&T4  combination  was  found.  In  this  setting,  without  any      data  
pertaining    to  subclinical  hypo-T ,   this   combination  therapy  should    
not  be  prescribed  in  routine  practice  for   them. 
                           After   starting  replacement  therapy  with  thyroxine,    
patients   have  to  undergo  follow-up   after  6–10  weeks.  With  the  
repeat  TSH  value,  thyroxine  dose  altered  accordingly.  This  is  to  
make  sure  that  TSH   falls  into   the  desired  range.  In  patients  who  
all  have,   dyslipidaemia  ie  before    starting   therapy  with  thyroxine ,    
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the  serum  lipid  profile   has  to  be  re-evaluated. This  follow-up,  is  
to  assess   sufficient  improvement  or  is  there   any  need  of  
pharmacological therapy  for  dyslipidaemia.  In  the  mean  time,        
re-evaluation  of   symptoms  of   hypoT,  in  patients  with  subclinical  
hypo-t ,  who   were  commenced   on  thyroxine  replacement  for 
possible   symptoms  of  hypoT.   This  is  very  important,  because  if   
at  all  any  benefit  from  thyroxine  replacement  in  subclinical     
hypo-T,   then  it  is  worthwhile  in  considering  prolonging  treatment  
for  lifelong.  If   following  a   three-six  months  of   therapeutic  trial,  
there  has  not  been  any  significant  symptomatic  improvement,  then   
it  is  time  to  consider  stopping   replacement  therapy.       
                            A   significant  number  of  persons  with  subclinical  
hypo-T   will  develop  clinical   hypoT.  This  progression  has  been  
found  to  be  around   6–10%  per  annum,  degree  of    TSH  elevation  
being  the  important  predictor .  On  the  other  side,  sub-normal  
thyroid   production   may  normalize   in  8–30%   of   subclinical  
hypo-T.  This   normalization depends  upon  baseline  TSH  values,  
autoantibody  against  thyroid  and  duration   &   frequency  of  follow-
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up.  As  a  result, in  most  of  the  patients,  thyroid  function  seems  to  
be   stable. 
                              If  a  patient  is  diagnosed  with  SCH,    then   the  
thyroid  function  has  to  be  re-evaluated  after  a  period  of   2-3 
months,  in  addition  to  thyroid  autoantibodies.  If   there  is  
normalization   of   thyroid   secretion,  no  more  testing  is  needed   in  
asymptomatic  patients  without   either  thyroid  autoantibodies    or   
goitre.   
                             In   patients  with   persistent  subclinical  hypo-T,  
thyroid  function  has  to  be  re-evaluated ,  once  in  six  months,  at 
least  for  the  first  two  years  &   thereafter  once  a  year  only. This 
Will  assess  any  tendency  to  progress  &  to  identify   consequent  
clinically  evident   hypoT. 
 
Objectives  of  Study: 
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                    a) To  find  out  the  type  of  thyroid  dysfunction  in 
metabolic  syndrome. 
                    b) To  find  out  the  association  of  thyroid  dysfunction 
with  the  components  of  metabolic syndrome. 
MATERIALS  AND  METHODS: 
 Source of Data 
                         Patients  attending  OPD  of  Dept  of  Internal  
Medicine, Tirunelveli Medical College Hospital, who are being 
diagnosed  as  metabolic  syndrome   and  fulfill  inclusion  and 
exclusion  criteria. 
 
Method  Of  Collection  of  Data 
Sample size:  
            100  subjects  with  MetS &  50 controls. 
Sampling Method : Simple  random  sampling 
  
Inclusion Criteria: 
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                        Patients  fulfilling  the criteria  for  metabolic  syndrome 
by  International  diabetic  foundation[IDF]   were  taken  into  study.  
                       Patients  with  metabolic  syndrome  not  on  any 
medications – newly  detected  metabolic  syndrome  patients. 
 
Exclusion Criteria: 
 1) Known  patients of hypothyroid or sub-clinical hypothyroid or 
hyperthyroidism  
2) Patients on  medications for diabetes  mellitus , hypertension , thyroid 
disorders and  dyslipidemia 
3) Patients  on  steroids 
4) Acutely  ill  patients 
5) Individuals  less  than  18 years age, who  can  not  give  consent.  
 
 
 
Method of study: 
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                          The  purpose  of  the  study  was  explained  to  the 
patient  and  informed  consent  was  obtained.   Data  was   collected 
using   a  pretested  proforma  meeting  the  objectives  of  the  study.  
Detailed  history and necessary investigations were undertaken.  Patients 
were  selected  for  study who  satisfied  all  the  inclusion  and  
exclusion  criteria.   Patients  were  diagnosed  having   metabolic 
syndrome   by   the,  
 “IDF criteria: 
                       Central  obesity – defined as waist circumference with 
ethnicity  specific  values (for south Asians :  ≥90 cm for Men and  
≥80cm  for  women  were  used) 
AND  any   two  of  the   following: 
• Raised triglycerides: > 150 mg/Dl (1.7 mmol/L), or  specific 
treatment  for  this  lipid  abnormality. 
• Reduced  HDL cholesterol: < 40 mg/Dl  in males, < 50 mg/dl in 
females, or  specific  treatment  for  this  lipid  abnormality 
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• Raised  blood  pressure:  systolic BP > 130   (or)  diastolic BP 
>85 mm Hg,  or  on   treatment  for  previously  diagnosed  
hypertension. 
• Raised  fasting  plasma  glucose FPG)>100 mg/dl ,   or  
previously  diagnosed  type 2  diabetes  mellitus” 
                               All  the  patients  enrolled  for  the  study,  were 
subjected  to  Thyroid  Function  Test.  Test  results  were  entered 
in  a  excel  sheet.  Meticulous  analysis  of  the  data  was  carried 
out. 
  INVESTIGATIONS 
1. Fasting  blood  sugar 
2. Lipid  profile  includes Triglycerides , HDL ,LDL, Total cholesterol 
3. Thyroid  assay includes T3 , T 4 , TSH     
4. Blood  pressure  recording  
5. Height , weight , waist circumference 
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                           RESULTS  AND  OBSERVATION  
Statistical  method:  
                        All  the  compiled  data  were  analysed  using  computer 
based  software. By  chi-square  test  p-value  was  calculated.               
P-value  < 0.05  was  considered   as  statistically significant. 
Age  distribution  among  the  subjects:                                
                           
                           Men                       Women 
     <30yrs    30-40yrs    >40yrs    <30yrs    30-40yrs     >40yrs 
MetS 3 27 9 8 38 15 
Control 5 13 7 5 18 2 
  
 
                             The  mean  age  of  the  MetS  subjects  was  around  36 
years.  The  mean  age  of  the  controls  was  found  to  be  34.7  years. 
This  difference  had   no  statistical  significance.  This  implied  that  the 
subjects  and  the  controls  were  comparable,  with  respect  to  their 
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age.  Thus  the  impact  of  age,  on  the  incidence  of  SCH,  was  
negated,  in  the  study   population. 
 
                
                          As  clearly  seen  from  the  above  chart,  more  than  
two-thirds of  the  subjects  fall  in  the  30-40yrs  age  category.  
Clustering  of  MetS  in  the  30-40yrs  age  group,  reveal  the  
deleterious  effects  of  the  wrong  life-style patterns  in  the  past  two  
decades. 
                                                      The  important thing  to  be  considered  is,  this  
30-40yrs  population,  is  the  backbone  of  a  growing  economy  like  
ours.  Hence,  any  health  related  issue,  affecting  this  population,  
will  produce  a  significant  negative  impact  on  the  nation’s  
development. 
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Figure 1 
 
 
    
Figure 2 
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                                      Sex  distribution  of  MetS  subjects: 
   Out  of  the  100   MetS  subjects,  39  were  male  and    61  were  
female. This  is  consistent with  the  results  of  many  observational  
studies, which found  out  that  the  incidence of metabolic  syndrome is   
1.5-2  times  higher  in  females compared  to  males.   
                                 p-value <0.05, this means,  the  sex  difference  noted  
in  the  prevalence  of  MetS  is   statistically  significant.    
                                 The  female  sex,  supposed  to  have  protective  
effect  against,  CV diseases,  is  the  easy  target  for  MetS.  This  strong  
Met S in men 39 
Met S in women 61 
      
 
clustering  of  CV risk  factors,  negates  the  natural  protection  for  
women,  against   cardiovascular  diseases.  
 
       
                  Figure 3 
 
                           The  popular  belief  that  premenopausal  women  have  
immunity  against  CV  diseases,  is  becoming  a  thing  of  past.  If  not  
taken  seriously,  this  will  haunt  the  future,  of  fertile  female  
population.  This  MetS,  being
question  mark  over  their  fertility  itself.    
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  associated  with  PCOS,  will  leave  a  
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Prevalence  of  SCH  in  MetS: 
 
Control    with   TSH<5.5 47 
Control   with   TSH>5.5   3 
Mets      with    TSH<5.5 79 
Mets      with   TSH>5.5 21 
  
                       Of  the  100  MetS  subjects,  21%  had  sub-clinical  
hypothyroidism.  Of  the  50  controls,  only  3  had SCH,  which means  
the  prevalence   among  the  control  population  is  around  6%  only. 
                         p-value <0.05, this means,  the difference  in  prevalence  
of   SCH   in  MetS  &  controls   is   statistically  significant.  
                         Both  SCH  and  MetS,  individually   being  CV risk  factors,  
their  combination  more  than  doubles  the  risk.  This  being  the  era  
of  non-communicable  diseases,  these  two  are  the  most  easily  
treatable  potential  risk  factors,  in  the  prevention  of  cardiovascular  
diseases. 
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                           Figure 4 
 
 
                      
 
                         Figure 5 
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 Sex-wise   prevalence   of   SCH: 
      Men   Women 
SCH in MetS      4      17 
SCH in control      1       2 
 
 
 
Figure 6 
 
                           More  than  80%  of  the  MetS  with  SCH  were  women.  
p-value  < 0.05,  statistically  significant.  
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Figure 7 
 
                         BMI  was  calculated  using  the  formula,
BMI=weight in kg/ height in m
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 of  Thyroid  function:  
              avg BMI 
26.7 
25.9 
21.4 
 
2
 . 
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                            As  expected,  BMI  was  significantly  higher  in  
MetS,  compared  to  the  controls.  But  the  difference  was  
not  significant, among  MetS with  SCH & MetS with  euthyroid  
status.   P-value >0.05,  implying,  no  statistical  significance.   
                      This  reiterates  the  “thin  fat  asian  phenotype”  
concept.   BMI  is  not  an  ideal  marker,  in  asian  population,  
when  compared  to  their   european  counterparts. 
                      Visceral  adiposity,  is   the   determining  factor,  in  
the  definition  of  metabolic  syndrome.  The  indian   urban 
population  don’t   indulge  in  regular  physical  activities.  So,  
their   muscle  mass  &  bone  mass  are  on  the  lower  side.  
This  the  reason  for  their  lower  BMI,  despite  of  their  look  
being   fatty.  
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Comparing  thyroid  function  with  MetS  components: 
Waist  circumference: 
        Men WC (cm)     Women WC(cm) 
MetS  with   SCH  100.3 93.6 
MetS  with   euthyroid  95.5 87.5 
 
                                        Waist  circumference  is  the  essential  
criteria  for   diagnosing  metabolic  syndrome.  Both  men  and  
women  with  MetS,  have  higher  WC,  compared  to  their  
euthyroid  counter-parts.  But,  this  difference  is  subtle,  with  
a  p-value>0.05,  statistically   insignificant.   
                                      Waist  circumference  is  the  indirect  
measure  of  visceral  adiposity.  This  has  been  also  found  to  
be  associated  with  the  incidence  of,  fatty  liver  and  NAFLD. 
 
      
 
Figure 8 
 
                                           Though  there  is  a  significant   arithmetic  
difference  in  the   waist  circumference  between 
groups,  the     p-value
significance.   
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Thyroid   function  vs   FBS: 
 
        Men FBS(mgs%)       Women FBS(mgs%) 
MetS   with  SCH  101 99.5 
MetS   with  euthyroid  95.5 98.7 
 
                                   Fasting  blood  sugar,  among  MetS,  was   in  the  
range  of  88-115mgs%,   with  the  average  value  being  97.7mgs%.  
Out  of  the  18  women  with  both  MetS & SCH,  8  had  a  FBS  value  
more  than  100mgs%.  Out  of  the  3  men  with  both  MetS & SCH,  2  
had  a  FBS  value  more  than  100mgs%. 
                                 The  difference  between  the  average  FBS,  
between  the   MetS   with  SCH  and  MetS  with  euthyroidism  is  only  
marginal. 
 
      
 
figure 9 
                                
               This  difference  in  FBS,  had  no 
the  p-value  was  >0.05.
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Thyroid   function   vs   TGL: 
 
 
 Men TGL(mgs%) Women TGL(mgs%) 
MetS   with   SCH  182.3 182.2 
MetS   with   euthyroid  139.5 141.2 
 
                                                                Fasting  Triglycerides,  among  
MetS,  was   in  the  range  of  112-230mgs%,   with  the  average  value  
being  148.7mgs%.  Out  of  the  18  women  with  both  MetS & SCH, all  
18  had  a  TGL  value  more  than  150mgs%.  Out  of  the  3  men  with  
both  MetS & SCH,  all  3  had  a  TGL  value  more  than  150mgs%. 
This  strongly  implies  that  raised  TGL,  is  an  integral  aspect  of  
patients  with  both  MetS &  SCH.    
 
      
 
               
Figure 10 
                        
                                  This  significant  difference  in  TGL  values,  among  
the  groups  is  authenticated  by  the  
TGL  value, more  than  150mgs%,  in  MetS  should  
to   screen  for  thyroid  dysfunction.
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Thyroid   function   vs   HDL: 
 
 Men  HDL(mgs%)  Women  HDL(mgs%) 
MetS   with  SCH  37 45.6 
MetS   with   euthyroid  36.2 46.5 
 
 
                                               Out  of  the  18  women  with  both  MetS & 
SCH,  14   had  a  HDL  value  less  than  50mgs%.  Out  of  the  3  men  
with  both  MetS & SCH,  2  had  a  HDL  value  less  than  40mgs%. 
                                            When  compared  to  their,  euthyroid  
counterparts,  both  men  and  women  with  MetS & SCH,  had  similar  
HDL  values.  This  rules  out  HDL,  being  a  definite  marker  to  screen  
for  thyroid  dysfunction  among  MetS  subjects.     
                                 This  also  stresses   the   fact  that,  in  MetS,         
non-HDL  control  is  more   important  than  improving  HDL  values  
alone. 
      
 
 
 
Figure 11 
 
                                  Almost  similar  HDL  values,  among  the  groups,  
leaves  this  criteria  being   insignificant,  with  the  
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Thyroid   function   vs   SBP: 
 
     Men SBP(mm Hg)     Women SBP(mm Hg) 
MetS   with   SCH  132.7 129.9 
MetS   with   euthyroid  136.6 131.4 
 
                                              Out  of  the  18  women  with  both  MetS & 
SCH,  7   had  a  SBP  value  more  than  130mm of Hg.  Out  of  the  3  
men  with  both  MetS & SCH,  1  had      SBP  value  more  than  130mm 
of Hg.                                    
                                  When  compared  to  their,  euthyroid  counterparts,  
both  men  and  women  with  MetS & SCH,  had  similar  SBP  values.  
This  rules  out  SBP,  being  a  definite  marker  to  screen  for  thyroid  
dysfunction  among  MetS  subjects.     
      
 
 
Figure 12 
 
                                  In  SCH,  the heart  rate  and  the  stroke  volume  are  
decreased.  This  results  in  a  fall  in  SBP  in  cimparison  to  MetS  with  
euthyroidism.  As  a  result,  for  the  difference  in  SBP,  among  the  
groups,   p-value  is   >0.05,  statistically  insignificant.
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Thyroid   function   vs   DBP: 
 
 
 
Men DBP(mm Hg) Women DBP(mm Hg) 
MetS   with   SCH  88 84.5 
MetS   with   euthyroid  88.5 85.7 
 
                                              Out  of  the  18  women  with  both  MetS & 
SCH,  9   had  a  DBP  value  more  than  85mm of Hg.  Out  of  the  3  
men  with  both  MetS & SCH,  1  had      DBP  value  more  than  85mm 
of Hg.                                    
                                 The  increase  in  DBP  is  due  to  increased  arterial  
stiffness  in  both  MetS  and  SCH.  But  when  compared  to  their,  
euthyroid  counterparts,  both  men  and  women  with  MetS & SCH,  
had  similar  DBP  values.  This  rules  out  SBP,  being  a  definite  
marker  to  screen  for  thyroid  dysfunction  among  MetS  subjects.     
      
 
Figure 13 
 
                                     Almost  similar  DBP  values,  among  the  MetS   
with  SCH  &  those  with  euthyroidism,  leaves  the    
the  association  is  statistically  insignificant.
 
 
82
83
84
85
86
87
88
89
MetS   with   SCH MetS   with   euthyroid 
82 
p-value  >0.05
 
 
,  ie,  
Men DBP(mm Hg)
Women DBP(mm Hg)
      
 
83 
 
 
 
 
DISCUSSION: 
 
 
                                In  our  study,  of  100  MetS,  majority  were  in  the  
30-40yrs  age  group,  highlighting  the  at-risk  population. Fast  
changing  food  habits  and  sedentary  life  style  pattern,  in  the  last  
two  decades,  could  be  the  answer  for  this  metabolic  abnormality. 
This  means,   economic  backbone  of  our  country,  is  amidst  a  crisis  
regarding  to  health  issues.     
                                  The  prevalence  of  MetS  in  women  is  more  than  
two  times, compared  to  men, in  this  study.  The  prevalence  of  SCH  
in  MetS,  was  found  to  be   21%,  when  compared  to  only  6%  in  
the  control  population.   This  association  with  SCH,  is  more  
frequent  among  women.   Due  to  increasing  sedentary  life style  
changes,  the  natural  immunity  against  cardiovascular  diseases  for  
the  women,  is  at  risk.   
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                                 The  thyroid  dysfunction  in  MetS,  is  statistically  
significantly  associated  with  the  serum  triglycerides,  followed  
closely  by  the  waist  circumference. This  association  is  not  found  
with  the  other  components  of  MetS. 
                                The  almost  nil  difference  among  the  subjects,  in  
regard  to  HDL,  once  again  reiterates  the  fact  that  non-HDL  
cholesterol  has  to  be  closely  monitored. 
                                  Unless,  strictly  managed  this  double  whammy  of  
SCH  and  MetS  will   result  in   a   heavy  toll,    in  our  growing  
economy.  Intensive  life-style,  has  to  be  initiated  in  a  much  
younger  population,  ie  school  going  children.  Only  this  primordial  
intervention,  can  produce  significant  changes,  helping  to  avert  this  
middle-age  menace.    
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Conclusion: 
                                     Due  to  the  alarming  rise,  in  CV  mortality  and  
morbidity,  the  people  at  risk  have  to  be  identified  at   the  earliest  
and  their  risk  factors  modified.  Hence,  diagnosing  MetS  should  
become  a  routine  practice  among  the  medical  fraternity.   
                                   Even  if  routine  screening  for  SCH  among  MetS  
is  not  feasible  among  all  patients,  Screening  for  thyroid  
dysfunction,  in  MetS,  especially  those  with  elevated  
triglycerides, has  to  become  a  part  of  treatment. 
                                  Patients  diagnosed  to  have a  double  jeopardy,  of  
MetS  with  SCH,  should  be  intensively  treated,  with  life-style  
Interventions  and  if  needed, with  pharmacological  therapy,  to  
achieve  the  desired  therapeutic  targets.   
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Limitations: 
                                     There  are  few  limitations  of  the  present  study, 
first  is,  this  being  a  cross-sectional  study,  a  cause  and  effect   
relationship  could  not  be  determined.  Further  large scale  cohort  
study  is needed  to  evaluate  the  deleterious  effect  of  subclinical  
hypothyroidism  on  cardiovascular  disease  and  metabolic  functions.       
.                            Second,  this  study  did  not  find  the  association 
between  TSH   and   many  components  of  MetS , the  reason  might 
be  there  were  only  few  subjects  with  subclinical hypothyroidism. 
Therefore,  large  epidemiological  studies  are  needed  to  evaluate  
the  relationship  between  SCH  in  patients  with  MetS. 
                                 Though  T3  and  T4  values  are  within  normal  
limits  with  isolated  TSH  elevation,  without  significant  symptoms,  
the  diagnosis  of  SCH  was  made,  in  this  study.    But,  FT4  was  not  
measured  due  to  non-feasibility.   
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Scope   for   future   study:   
                            The  reason  for  subclinical  hypothyroidism,  among  
MetS,  could  be  cytokine  mediated  injury.  MetS  is  a  well  known  
pro-inflammatory  state,  causing  excess  release  of  interleukins  and 
interferons. 
                      This  augmented  cytokine  release  may  mediate  injury  
to   thyroid  follicles,  exposing  the  enzymes  on  the  apical  border  of  
follicles  to  TPO  antibodies  which  may  then bind  to  autoantigens  
and  fix  the  complement  leading  to hypothyroidism.  This  proposed  
mechanism,  has  to  be  scientifically  studied,  by  comparing  these   
inflammatory markers  against  TSH  and  TPO  antibody. 
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ABBREVIATION 
MetS     ---     metabolic  syndrome 
SCH        ---     subclinical  hypothyroidism 
WC         ---     waist  circumference 
FBS         ---     Fasting blood sugar   
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HDL        ---     high density lipoprotein 
TGL         ---     triglyceride 
LDL          ---     low  density lipoprotein 
VLDL       ---      very low density lipoprotein  
SBP         ---      systolic  blood pressure 
DBP        ---      diastolic  blood pressure 
CVD        ---       cardiovascular diseases 
CRP         ---      C-reactive protein 
TSH         ---      thyroid stimulating  hormone 
apoA       ---      apolipoprotein A 
apoB       ---      apolipoprotein B 
Lp-a         ---      lipoprotein a 
 PAI          ---     plasminogen activator inhibitor    
 
 
                                 PROFORMA 
Name                             :        
Age                                 : 
Sex  : 
      
 
96 
Height : 
Weight  : 
BMI  : 
BP                             : 
Waist  circumference   : 
Medical history             : 
Current  medications   : 
Investigations                 :     
FBS 
TGL 
HDL 
 
 
                                      MASTER  CHART 
MetS  subjects: 
NAME AGE SEX BMI WC FBS TGL HDL SBP DBP TSH 
           
SUBHA 32 F 26 92 104 162 50 110 74 5.9 
MYMOON 29 F 26.4 96 98 188 40 126 80 7.4 
DURATCHI 47 F 28.4 102 110 210 45 140 90 9.1 
STELLA 36 F 26.3 94 97 174 54 135 95 7 
ESWARI 46 F 26.2 90 102 162 44 130 85 8.4 
STEFFI 28 F 25.3 92 89 198 47 124 70 7.7 
GAYATHRI 38 F 23.9 89 108 172 52 116 76 6.8 
CHELLAM 40 F 28.1 95 94 185 41 145 94 9.2 
      
 
97 
RIYANA 45 F 25.3 90 115 202 46 130 78 8.1 
JEYA 46 F 25.9 90 104 230 43 140 90 6.4 
NANDHINI 29 F 26.4 92 92 162 48 126 87 5.9 
HELEN 37 F 28.1 95 88 171 47 124 78 9.2 
ALAGU 39 F 26.4 88 108 167 42 130 85 7.1 
ZAHIDHA 40 F 24.9 95 94 178 39 140 82 8.2 
DHANAM 44 F 27.4 97 97 182 52 140 90 8.7 
GNANAM 32 F 30.2 101 90 190 44 118 90 7.6 
MANGAI 38 F 26.9 93 102 165 41 134 92 7.2 
KRISHNAN 38 M 28.4 102 98 185 39 135 90 7.6 
ASHWIN 28 M 25.3 95 100 170 37 130 82 6.8 
SRIDHAR 33 M 29.4 104 104 192 35 135 92 9.2 
SUBRAMANI 40 M 24.3 99 96 164 40 140 90 8.8 
           
           
           
SHANTHI 38 F 23.8    101 138 40 127 76 3.2 
MALLIGA 42 F 24.6 90 95 142 42 138 90 3.7 
LAKSHMI 36 F 24.2 83 110 122 45 130 80 2.2 
JEYA 28 F 25 87 98 152 47 120 88 4.2 
ALAGAMMAL 39 F 24.3 90 104 145 47 130 90 2.5 
MENAKA 44 F 23.8 92 97 121 42 140 86 3.6 
GOMATHI 38 F 26 87 92 137 41 135 92 4.5 
KARPAGAM 40 F 25.6 88 108 143 55 140 90 4 
JEBA 46 F 24.7 82 102 150 52 144 90 2.4 
PRINCY 32 F 23.9 84 105 128 51 138 88 2.8 
GEETHA 39 F 25.2 88 102 143 55 136 92 3.2 
LAVANYA 35 F 26.8 89 89 110 47 140 95 3.4 
MANGAMMAL 45 F 25.9 91 102 154 58 135 88 2.1 
SELVI 26 F 22.9 83 88 138 41 130 92 3.7 
PREMA 48 F 23.7 82 92 120 42 144 96 3.1 
LALITHA 41 F 24.1 84 103 118 48 126 80 4.8 
FATHIMA 28 F 23.8 85 95 145 42 135 88 4.2 
DHIVYA 30 F 25.1 90 102 155 47 127 82 2.6 
ARASI 39 F 23.8 85 88 162 49 120 90 2.3 
POONKODI 42 F 24.7 82 100 142 48 138 86 3.6 
PACKIAM 37 F 25.2 88 94 174 54 146 92 4.1 
PETCHI 40 F 23.3 84 110 124 46 135 80 4.3 
LAKSHMI 36 F 26.7 91 96 139 48 136 90 4.2 
MARIAMMAL 32 F 25.9 85 102 148 41 110 70 3.7 
NAGALAKSHMI 38 F 26.2 87 110 146 50 124 90 3.5 
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ESAKKI 33 F 23.7 84 102 137 48 108 70 2.1 
PANDEESWARI 37 F 25.4 88 98 124 46 136 92 2.7 
DURGA 42 F 23.6 81 88 117 42 140 88 2.4 
ANDAL 41 F 25.8 87 98 149 44 130 90 3.5 
FLORA 32 F 26.8 89 102 157 54 112 76 3.2 
KALYANI 33 F 23.5 83 89 146 43 138 88 4.8 
PRIYA 31 F 29.6 98 89 182 47 130 87 3.4 
SEETHA 35 F 27.3 91 104 132 44 124 80 3.8 
AISHWARYA 26 F 25.8 92 98 146 44 128 88 4.7 
SASIKALA 35 F 27.9 94 87 134 44 126 88 2.4 
RAJESWARI 38 F 25.7 89 105 129 54 138 86 2.9 
THILAGAM 39 F 23.9 87 98 167 54 140 92 4.2 
MARY 37 F 27.2 93 110 138 42 110 70 3.7 
SUSEELA 34 F 24.7 92 85 125 38 130 92 3.1 
BHANU 33 F 25.3 89 102 118 48 138 84 1.9 
KALIAMMAL 38 F 24.1 83 84 116 42 144 88 2.6 
PASUVATHI 42 F 24.8 85 115 142 52 150 86 4.2 
VANI 29 F 25.6 88 96 158 39 122 74 1.8 
ESWARI 39 F 27.1 92 108 146 43 110 70 4.3 
           
           
           
           
RAM KUMAR 36 M 28.4 94 98 125 36 124 90 3.7 
SARAVANAN 38 M 26.5 93 89 137 32 126 86 3.4 
ALEX 40 M 26.3 97 110 148 37 126 74 2.9 
FAKRUDEEN 42 M 27.1 98 85 160 33 128 84 2.2 
MANIKANDAN 37 M 26.5 92 82 139 36 128 90 2.6 
KARUPPIYAH 44 M 27.2 96 92 128 38 128 92 1.8 
KATHIR 28 M 29.4 105 98 148 35 128 88 3.2 
RAHMAN 34 M 28.3 97 87 155 39 130 82 3.7 
PANDIAN 38 M 26.4 92 104 130 44 130 94 2.8 
RAJA 32 M 26.9 97 98 117 32 134 90 2.6 
ALAGAR 41 M 27.4 93 89 152 36 136 84 4.7 
RANGASAMY 46 M 29.1 99 102 149 38 136 88 3.9 
BRITTO 36 M 26.3 94 82 137 36 136 82 4.2 
BALAJI 32 M 26.1 92 94 126 32 136 95 1.5 
SAMPATH 40 M 27.8 100 92 158 43 136 94 2.9 
DURAI 31 M 27.4 98 98 160 36 136 86 2.4 
GANAPATHY 37 M 27.3 99 110 145 38 138 82 3.5 
MOHAMMED 42 M 28.4 93 84 142 38 138 96 4.1 
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VENKATACHALAM 48 M 26.8 97 102 137 37 138 80 3.8 
ESAKKI 39 M 27.6 95 88 128 38 138 100 3.2 
JOHNSON 38 M 29.8 98 92 126 34 138 94 2.5 
VADIVEL 41 M 25.7 93 98 115 32 138 96 1.9 
NARAYANAN 34 M 25.3 96 90 140 37 138 92 2.3 
MUTHUSAMY 31 M 26.1 94 97 138 33 140 90 2 
KUMAR 39 M 26.8 92 115 123 38 140 84 4.3 
PANDY 41 M 24.9 94 98 156 44 140 96 3.9 
VISHNU 29 M 24.6 91 89 144 33 142 88 2.9 
SHIVA 38 M 26.7 101 106 115 32 142 90 3.6 
JERRY 32 M 23.1 92 102 150 36 142 88 4.5 
SURULI 30 M 27.4 96 92 146 36 142 84 4.1 
VIGNESH 37 M 23.8 93 105 132 31 144 84 2.1 
MOHAN 41 M 26.7 98 98 152 38 144 82 1.8 
BALACHANDAR 39 M 26.3 95 88 117 36 145 98 2.3 
CHANDRAN 33 M 25.8 92 102 145 34 146 82 3.7 
PRABHU 36 M 28.4 98 88 160 38 150 80 4.1 
Controls: 
 
age  sex BMI waist circumference FBS TGL HDL SBP DBP TSH 
           
PALANIAMMAL 38 F 21.6 76 80 115 49 110 78 2.4 
SHEEBA 27 F 20.7 78 90 120 52 124 80 3.6 
NAGU 29 F 21.4 74 87 122 55 128 78 3.8 
SUBHASREE 34 F 19.9 79 91 105 48 130 82 4.4 
VASUKI 37 F 22.2 80 92 132 52 110 78 2.1 
ANU 31 F 20.5 77 90 115 50 120 80 1.9 
KOTHAI 40 F 23.9 82 92 164 52 120 82 7.2 
THILAGAVATHI 36 F 19.4 74 96 108 47 114 78 4.2 
SUDHA 33 F 21.3 79 88 118 43 114 80 3.9 
GOLDY 29 F 20.6 72 90 127 54 126 82 3.3 
KALYANI 41 F 22.8 78 87 109 53 130 80 3.5 
MANGAI 43 F 20.7 81 84 128 49 110 74 2.8 
SUSEELA 38 F 19.6 73 97 110 50 120 76 2.5 
KARTHIGA 35 F 23.4 76 83 128 53 130 78 3.9 
LATHA 26 F 24.2 84 88 159 51 110 78 6.8 
SOUNDHARYA 30 F 21.2 75 92 145 47 126 78 4.7 
KALISWARI 36 F 22.1 80 85 98 46 124 84 4.2 
AVUDAIAMMAL 38 F 19.8 71 90 132 51 128 76 3.9 
VANITHA 31 F 22.7 77 82 104 47 114 74 2.2 
VIJAYA 33 F 20.5 75 86 123 48 124 76 1.9 
ULAGAMMAL 30 F 21.8 73 88 108 49 110 74 4.2 
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SAROJA 29 F 22.4 79 91 117 54 124 78 4.6 
KOKILA 34 F 21.3 74 84 105 51 118 80 4.1 
RADHA 38 F 23.2 82 89 126 49 114 78 2.9 
PERIANAYAGI 36 F 22.8 76 82 145 52 120 84 3.9 
ARUMUGAM 28 M 23.1 84 84 130 44 128 84 3.2 
PRAKASH 32 M 19.8 82 88 124 42 116 78 2.9 
VELAN 39 M 18.7 80 90 115 40 118 82 3.7 
KINGSLY 31 M 22.1 84 92 132 39 124 76 3.2 
RAJESH 40 M 20.7 88 90 112 41 130 82 1.2 
SUNDARAM 45 M 19.4 82 94 108 37 126 82 1.7 
SRIDHARAN 38 M 23.9 90 96 172 42 124 80 7.3 
ARAVIND 29 M 20.1 86 88 132 44 116 76 3.9 
BARANI 33 M 22.1 82 81 107 42 112 70 4.2 
GUNAALAN 38 M 21.4 85 86 98 42 124 74 3.8 
MUTHURAJ 40 M 21.9 88 94 132 38 114 74 2.7 
SUDALAI 35 M 19.9 81 78 121 36 120 80 2.4 
KUMARESAN 33 M 20.7 82 83 116 43 116 82 1.9 
SYED IBRAHIM 44 M 20.5 86 96 104 41 126 82 3.8 
KARTHIKEYAN 39 M 22.4 83 91 128 40 122 76 4.4 
KOMBAIYAH 41 M 21.5 82 90 110 39 122 82 4.6 
ARUL 26 M 21.9 81 79 98 41 110 70 3.5 
RAMAN 36 M 20.5 80 86 124 44 116 76 3.3 
LINGAM 42 M 22.7 91 81 142 41 132 84 3.8 
VIJAYAN 31 M 21.3 89 89 136 39 120 78 1.5 
THANGASAMY 38 M 23.5 92 94 118 37 118 74 1.8 
PRABHU 28 M 21.5 84 86 109 44 130 90 4.1 
MAHESH 35 M 20.2 82 92 132 42 124 72 2.7 
ANBU 28 M 19.6 80 90 142 41 128 78 2.8 
RAJESH 45 M 20.6 81 94 139 47 124 80 3.3 
 
